AustraliaBreaking News

Neuren Pharmaceuticals (ASX:NEU) secures FDA feedback for NNZ-2591, validating its HIE study path and Pitt Hopkins trial endpoints for a 2026 launch.

Matsa Resources (ASX:MAT) said that AngloGold Ashanti Australia has commenced exploration drilling on the M39/599 tenement.

G11 Resources (ASX:G11) commenced its maiden drilling program at the Zig Zag Cu-Au prospect within the 100% owned Sedgwick Project.

Queensland-based Graphinex has finalised a major agreement to supply graphite to a new Japanese refinery.

Green & Gold Minerals (ASX:GG1) bolstered its exploration pipeline by acquiring the Burlington Project.

Australia's sovereign wealth fund has delivered a powerhouse performance for 2025, with the Future Fund reporting a 12.4% annual return that added a staggering $29.54 billion to its coffers.

Cyclopharm (ASX:CYC) announced a capital raise totaling $16 million to accelerate the commercialisation of its flagship radiopharmaceutical product, Technegas, within the United States market.

Orpheus Uranium (ASX:ORP) has announced a $4.4 million capital raise through a strategic share placement to accelerate its exploration programs across Australia.

Elanor Investors Group (ASX:ENN) has terminated its management and property agreements with the Elanor Commercial Property Fund.

Island Pharmaceuticals (ASX:ILA) secured $9 million in strategic funding, raised through a placement of approximately 25.7 million new ordinary shares priced at $0.35 each.

Bellavista Resources (ASX:BVR) completed a heavily oversubscribed bookbuild, securing $35 million through a two-tranche placement.

Caspin Resources (ASX:CPN) has kicked off its 2026 exploration season, launching simultaneous high-impact programs across its Bygoo Tin and Weethalle Gold projects in New South Wales.